[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.168.21. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

Year

Day

December 8, 2016
Viewpoint

Body Image Disorders and Abuse of Anabolic-Androgenic Steroids Among Men

Abstract Full Text
free access
JAMA. Published online December 8, 2016. doi:10.1001/jama.2016.17441

This Viewpoint discusses the health risks of the use of anabolic-androgenic steroids by men with muscle dysmorphia, a form of body image disorder characterized by obsessive preoccupation with a muscular appearance.

December 6, 2016
Viewpoint

Revised CIOMS International Ethical Guidelines for Health-Related Research Involving Humans

Abstract Full Text
free access
JAMA. Published online December 6, 2016. doi:10.1001/jama.2016.18977

This Viewpoint summarizes revisions made in 2016 to the Council for International Organizations of Medical Sciences’ (CIOMS) International Ethical Guidelines for Health-Related Research Involving Humans.

December 1, 2016
Editorial

Scientific Evidence and Financial Obligations to Ensure Access to Biosimilars for Cancer Treatment

Abstract Full Text
free access
JAMA. Published online December 1, 2016. doi:10.1001/jama.2016.18743

Biosimilar Therapy for ERBB2 (HER2)–Positive Breast CancerClose Enough?

Abstract Full Text
free access
JAMA. Published online December 1, 2016. doi:10.1001/jama.2016.18979
Original Investigation

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast CancerA Randomized Clinical Trial

Abstract Full Text
free access
JAMA. Published online December 1, 2016. doi:10.1001/jama.2016.18305

This randomized clinical trial compares the overall response rate and safety of a proposed trastuzumab biosimilar vs trastuzumab and a taxane among women with ERBB2 (HER2)–positive metastatic breast cancer.

×